AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA - Nasdaq

AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA  Nasdaq

Shares of AbbVie Inc. ABBV rose 2.3% on Aug 16 after its oral JAK inhibitor, upadacitinib, received FDA approval for the treatment of.



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases